Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy. Two phase 3 studies are currently underway testing riliprubart in peopl ...

The hereditary neuropathy with liability to pressure palsies (HNPP) is an autossomal dominant disorder characterized by recurrent sensory and motor mononeuropathies that tend to occur at entrapment ...